Indo US Bio-TechNSE:INDOUS +0.96%63 Altman Z-Score is 4.59 as of Jul. 05, 2026, which is 3% below its 10-year median of 4.72. GuruFocus rates NSE:INDOUS with a GF Score™ of 63/100 and a GF Value™ of ₹292.74 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 250 Agriculture companies, Indo US Bio-Tech ranks better than 79.2% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 4.59 is strong.
Indo US Bio-Tech has a Altman Z-Score of 4.59, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Indo US Bio-Tech's Altman Z-Score or its related term are showing as below:
NSE:INDOUS'
s Altman Z-Score Range Over the Past 10 Years
Min: 2.7 Med: 4.72 Max: 14.67
Current: 4.59
During the past 13 years, Indo US Bio-Tech's highest Altman Z-Score was 14.67. The lowest was 2.70. And the median was 4.72.
Indo US Bio-Tech (NSE:INDOUS) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Indo US Bio-Tech Altman Z-Score Related Terms
Indo US Bio-Tech Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Indo US Bio-Tech's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INDOUS vs CTVA, CF, MOS: Altman Z-Score Comparison
For the Agricultural Inputs subindustry, Indo US Bio-Tech's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indo US Bio-Tech Altman Z-Score vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Indo US Bio-Tech's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Indo US Bio-Tech's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Indo US Bio-Tech's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.6099
+
1.4
*
0
+
3.3
*
0.1214
+
0.6
*
4.3834
+
1.0
*
0.8298
=
4.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Indo US Bio-Tech (NSE:INDOUS) has a Altman Z-Score of 4.59 as of Jul. 05, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Indo US Bio-Tech and its competitors. This is near median its historical median of 4.72. Over the past decade, Indo US Bio-Tech's Altman Z-Score has ranged from 2.70 to 14.67. According to the industry distribution chart, Indo US Bio-Tech ranks #52 out of 250 companies in the Agriculture industry, placing it in the top 20.8%.
Is Indo US Bio-Tech's Altman Z-Score too high?
Indo US Bio-Tech's current Altman Z-Score of 4.59 is near median its 10-year median of 4.72. Over the past 10 years, this metric has ranged from a low of 2.70 to a high of 14.67. The Agriculture industry median Altman Z-Score is 2.69. Indo US Bio-Tech's value of 4.59 is 70.9% above this industry median. Based on the distribution chart, Indo US Bio-Tech ranks #52 out of 250 companies in the Agriculture industry, which is in the top quartile — a strong position relative to peers. Overall, Indo US Bio-Tech has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indo US Bio-Tech's Altman Z-Score compare to CTVA and CF?
According to the Agriculture industry distribution chart, Indo US Bio-Tech ranks #52 out of 250 companies for Altman Z-Score. This places Indo US Bio-Tech in the top 21% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.69. Indo US Bio-Tech's value of 4.59 is 70.9% above this benchmark. Historically, Indo US Bio-Tech's own Altman Z-Score has ranged from 2.70 to 14.67 over the past decade. While the company's 10-year median is 4.72 vs. the industry median of 2.69, Indo US Bio-Tech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for an Agriculture company?
The median Altman Z-Score among Agriculture companies is 2.69, based on 250 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indo US Bio-Tech's current Altman Z-Score of 4.59 is 70.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Indo US Bio-Tech and its competitors. For the Agriculture industry, the median Altman Z-Score is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indo US Bio-Tech's current Altman Z-Score is 4.59, which is near median its own 10-year median of 4.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo US Bio-Tech stock overvalued right now?
Based on GuruFocus' analysis, Indo US Bio-Tech (NSE:INDOUS) is currently considered Possible Value Trap. The stock's GF Value™ is ₹292.74, compared to a current price of ₹89.15 — trading 69.5% below its estimated fair value. The current Altman Z-Score is 4.59, which is near median its 10-year median of 4.72 and 70.9% above the Agriculture industry median of 2.69. Indo US Bio-Tech's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Indo US Bio-Tech (NSE:INDOUS), the current Altman Z-Score is 4.59 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indo US Bio-Tech (NSE:INDOUS) Overvalued in 2026?
Based on GuruFocus' analysis, Indo US Bio-Tech stock appears to be undervalued.
The current stock price of ₹89.15 is trading 69.5% below its estimated GF Value™ of ₹292.74.
GuruFocus considers Indo US Bio-Tech to be Possible Value Trap.
Key valuation signals for NSE:INDOUS:
Altman Z-Score: 4.59 (near median its 10-year median of 4.72)
GF Value™: ₹292.74 vs. price of ₹89.15 (69.5% below fair value)
Industry Position: 70.9% above the Agriculture median (#52 of 250)
No single metric tells the full story. See the NSE:INDOUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indo US Bio-Tech Ltd is a specialized agriculture seed company. It is involved in crop research and development through breeding, production of seeds, processing, packing, and marketing of high-performing hybrid and open-pollinated varieties of crops. The company's product portfolio includes a diversified variety of agricultural seeds, namely vegetable seeds, oil seeds, pulses seeds, cereals seeds, spices seeds used in cultivating all kinds of vegetables, pulses, crops like tomato, okra, brinjal, onion, bit root, cucumber, bottle gourd, groundnut, mustard, bajra, wheat, etc.
63GF Score
Get the complete analysis for NSE:INDOUS
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDOUS has been successfully added to your 
